Jared Nielsen
Ophthalmology · West Des Moines, IANPI 1467409383
Payments from drug & device makers
Across 325 payments — averaging $9639.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Genentech, Inc.$1.9M
- Novartis$745K
- Regeneron$273K
- Genentech USA, Inc.$37K
- Bayer$34K
- Apellis Pharmaceuticals, Inc.$33K
- plus $84K from 15 others
Across 2 payments — averaging $3457.75 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- F. Hoffmann-la Roche AG$7K
What the payments were for
- Consulting fees$68,48659%
- Speaking & faculty fees$33,28529%
- Travel & lodging$8,0167%
- Food & beverage$3,0313%
- Ownership interest$2,5812%
- Other$1,1501%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Genentech, Inc. | 191 | $1,927,495 |
| Novartis | 23 | $745,090 |
| Regeneron | 2 | $272,820 |
| Genentech USA, Inc. | 18 | $36,620 |
| Bayer | 5 | $33,549 |
| Apellis Pharmaceuticals, Inc. | 22 | $33,185 |
| AstraZeneca | 2 | $24,791 |
| F. Hoffmann-la Roche AG | 2 | $16,003 |
| AbbVie | 2 | $9,986 |
| Regeneron Healthcare Solutions, Inc. | 11 | $8,617 |
| Novartis Pharma AG | 1 | $5,125 |
| Astellas Pharma US Inc | 3 | $4,603 |
| US Retina LLC | 19 | $3,767 |
| Alimera Sciences, Inc. | 3 | $3,518 |
| Novo Nordisk AS | 5 | $2,805 |
| Alcon Research LLC | 2 | $2,100 |
| Coherus Oncology, Inc. | 1 | $1,350 |
| Bausch & Lomb Americas Inc. | 7 | $643 |
| Alcon | 4 | $445 |
| Dutch Ophthalmic, USA | 1 | $127 |
| Biogen | 1 | $105 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- SUSVIMO$22,070
- BEOVU$16,161
- VABYSMO$12,409
- EYLEA$8,390
- Syfovre$8,176
- Lucentis$4,235
- EYLEA HD$2,820
- Izervay$2,603
- Non-Covered Product$2,203
- Cimerli$1,350
- NGENUITY$300
- EVA, combined machine$127
- TISSUEBLUE$127
- BUPARLISIB$122
- Clareon$100
How this compares
$3,132,744 in reported general payments places this provider in the 95th percentile of 172 ophthalmology providers in Iowa.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Prednisolone Acetate | 43 | $2,333 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 30 | $420 |
| MoxifloxacinMoxifloxacin Hcl | 15 | $313 |
| Brimonidine Tartrate | 19 | $181 |
| Latanoprost | 22 | $157 |
Paid to pharmacies, not to this prescriber.
Other ophthalmology in West Des Moines
- Matthew RauenWest Des Moines$756K
- Kyle AllimanWest Des Moines$100K
- Frederick BlodiWest Des Moines$6K
- Valerie KounkelWest Des Moines$4K
- George ClavennaWest Des Moines$4K
- Andrew SteffensmeierWest Des Moines$3K
- Matthew RaeckerWest Des Moines$3K
- Mohamed HassanWest Des Moines$3K
- Steven JohnsonWest Des Moines$3K
- David SaggauWest Des Moines$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.